489 related articles for article (PubMed ID: 21326079)
21. [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model].
Ma RX; Xu Y; Zhang J; Li YS; Liu LQ
Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):117-22. PubMed ID: 22490812
[TBL] [Abstract][Full Text] [Related]
22. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
Nishiyama A; Nakagawa T; Kobori H; Nagai Y; Okada N; Konishi Y; Morikawa T; Okumura M; Meda I; Kiyomoto H; Hosomi N; Mori T; Ito S; Imanishi M
J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221
[TBL] [Abstract][Full Text] [Related]
23. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus.
Amazonas RB; Sanita Rde A; Kawachi H; de Faria JB
Nephron Physiol; 2007; 107(2):p57-64. PubMed ID: 17890883
[TBL] [Abstract][Full Text] [Related]
24. Emodin ameliorates high glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo.
Chen T; Zheng LY; Xiao W; Gui D; Wang X; Wang N
Cell Physiol Biochem; 2015; 35(4):1425-36. PubMed ID: 25791065
[TBL] [Abstract][Full Text] [Related]
25. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
26. Panax Notoginseng Ameliorates Podocyte EMT by Targeting the Wnt/β-Catenin Signaling Pathway in STZ-Induced Diabetic Rats.
Xie L; Zhai R; Chen T; Gao C; Xue R; Wang N; Wang J; Xu Y; Gui D
Drug Des Devel Ther; 2020; 14():527-538. PubMed ID: 32103895
[TBL] [Abstract][Full Text] [Related]
27. Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy.
Wang N; Wei RB; Li P; Li QP; Yang X; Yang Y; Huang MJ; Wang R; Yin Z; Lv Y; Chen XM
J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320316646884. PubMed ID: 27169889
[TBL] [Abstract][Full Text] [Related]
28. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.
Bonnet F; Candido R; Carey RM; Casley D; Russo LM; Osicka TM; Cooper ME; Cao Z
J Hypertens; 2002 Aug; 20(8):1615-24. PubMed ID: 12172324
[TBL] [Abstract][Full Text] [Related]
29. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
30. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
[TBL] [Abstract][Full Text] [Related]
31. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
32. Valsartan inhibits amylin-induced podocyte damage.
Huang F; Wang Q; Ma X; Wu L; Guo F; Qin G
Microvasc Res; 2016 Jul; 106():101-9. PubMed ID: 27102209
[TBL] [Abstract][Full Text] [Related]
33. FK506 ameliorates podocyte injury in type 2 diabetic nephropathy by down-regulating TRPC6 and NFAT expression.
Ma R; Liu L; Jiang W; Yu Y; Song H
Int J Clin Exp Pathol; 2015; 8(11):14063-74. PubMed ID: 26823720
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats.
Peng T; Chang X; Wang J; Zhen J; Yang X; Hu Z
Mol Med Rep; 2017 May; 15(5):3172-3178. PubMed ID: 28339051
[TBL] [Abstract][Full Text] [Related]
35. The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats.
Kim SH; Jang YW; Hwang P; Kim HJ; Han GY; Kim CW
Exp Mol Med; 2012 Jan; 44(1):45-51. PubMed ID: 22056625
[TBL] [Abstract][Full Text] [Related]
36. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
Ren X; Guan G; Liu G; Liu G
Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
[TBL] [Abstract][Full Text] [Related]
37. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
[TBL] [Abstract][Full Text] [Related]
38. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
[TBL] [Abstract][Full Text] [Related]
39. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
[TBL] [Abstract][Full Text] [Related]
40. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
O'Donnell MP; Crary GS; Oda H; Kasiske BL; Powell JR; Keane WF
Kidney Int Suppl; 1997 Dec; 63():S218-20. PubMed ID: 9407464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
